Employees: 656
Size SD Biosensor (137310.KS) is a South Korea Health Care company (Electronic Equipment/Instruments) with a market value of $647M, the 306th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩7,170 on 18 Nov 2026.
Performance Over six months the shares fell 14.8%, against -27.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 9.6% over the last twelve months (peer median +9.1%); the operating margin is -6.2% (peer median 6.6%).
Valuation It trades at 1.0× enterprise value to sales against a peer median of 1.3× (8th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is -16%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.1 points below its cost of capital (5.5% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩763B | ₩711B | ₩695B | ₩656B | ₩2.93T |
| Revenue growth | — | +2% | +6% | -78% | — |
| Gross profit | ₩275B | ₩224B | ₩241B | ₩29.2B | ₩1.38T |
| EBITDA | ₩71.1B | ₩51.4B | ₩87.2B | -₩111B | ₩1.19T |
| Net income | -₩831B | -₩512B | -₩98.4B | -₩468B | ₩911B |
| Free cash flow | ₩31.2B | ₩300B | ₩77.7B | -₩385B | ₩593B |
| Capital expenditure | ₩50.5B | ₩57.5B | ₩80.9B | ₩145B | ₩300B |
| Total debt | ₩97.9B | ₩669B | ₩607B | ₩604B | ₩24.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 137310.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.4% | -8.3% | 2nd highest of 21 |
| 6-month return | -14.8% | -27.0% | 7th highest of 21 |
| Distance from 52-week high | -26.9% | -49.0% | 4th highest of 21 |
| Revenue growth (TTM) | +9.6% | +9.1% | 10th highest of 21 |
| Operating margin | -6.2% | 6.6% | 7th lowest of 21 |
| EV / Sales | 1.0× | 1.3× | 8th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 3.3% | -6.6% | 2nd most demanding of 10 |
| Growth delivered (Del g) | -15.9% | +12.2% | lowest of 10 |
| Hurdle (Req g minus delivered) | +19.1 pp | -15.7 pp | most demanding of 10 |
| ROIC minus cost of capital | -7.1 pp | -0.4 pp | 6th lowest of 20 |
| EV / EBITDA | 10.3× | 7.4× | 4th most expensive of 14 |
| Net debt / EBITDA | -1.9× | 1.2× | 4th least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SD Biosensor 137310.KS | South Korea | $647M | -15% | +10% | -6% | 1.0× | 3.3% | -15.9% |
| Livsmed 491000.KS | South Korea | $687M | -47% | +89% | -77% | 18.1× | n/a | n/a |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 0.5× | -6.6% | +5.4% |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 0.9× | -3.1% | +12.6% |
| HK inno.N 195940.KS | South Korea | $783M | -28% | +7% | 12% | 1.3× | -4.7% | +12.2% |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 1.2× | -6.7% | -15.9% |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 0.9× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 1.2× | -4.2% | +10.6% |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 1.2× | n/a | n/a |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | 0.8× | n/a | n/a |
| Myung in Pharm 317450.KS | South Korea | $466M | -20% | +7% | 35% | 0.7× | n/a | n/a |
| PROTEINA 468530.KS | South Korea | $460M | +5% | -59% | -1,178% | 410.3× | n/a | n/a |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -83% | 25.2× | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | 11.8× | n/a | n/a |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 7.5× | -10.2% | +18.1% |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | 84.4× | n/a | n/a |
| Dong-A Socio 000640.KS | South Korea | $447M | -8% | +11% | 7% | 0.7× | -6.6% | +12.8% |
| L&C BIO 290650.KS | South Korea | $943M | -37% | +65% | 20% | 9.7× | 32.6% | +21.0% |
| Hyundai Bioscience 048410.KS | South Korea | $424M | -50% | +78% | -580% | 164.0× | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $423M | -26% | +9% | 13% | 0.7× | -15.4% | +7.2% |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | 215.1× | n/a | n/a |